Thermo Fisher Scientific Long-Term Debt increased by 9.6% to $42.95B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 26.4%, from $33.99B to $42.95B. Over 5 years (FY 2020 to FY 2025), Long-Term Debt shows an upward trend with a 15.4% CAGR.
High levels indicate significant leverage, which can amplify returns but also increase financial risk, especially in rising interest rate environments.
Financial obligations with maturity dates extending beyond one year. This represents the core long-term financing struct...
Compared against industry peers using debt-to-equity or net debt-to-EBITDA ratios to assess relative financial health.
long_term_debt| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $18.77B | $21.60B | $34.67B | $33.06B | $30.06B | $28.94B | $34.28B | $35.05B | $33.81B | $35.08B | $34.73B | $35.39B | $35.20B | $35.11B | $31.07B | $33.99B | $35.03B | $35.48B | $39.17B | $42.95B |
| QoQ Change | — | +15.0% | +60.5% | -4.6% | -9.1% | -3.7% | +18.4% | +2.3% | -3.6% | +3.8% | -1.0% | +1.9% | -0.6% | -0.2% | -11.5% | +9.4% | +3.1% | +1.3% | +10.4% | +9.6% |
| YoY Change | — | — | — | — | +60.1% | +34.0% | -1.1% | +6.0% | +12.5% | +21.2% | +1.3% | +1.0% | +4.1% | +0.1% | -10.5% | -4.0% | -0.5% | +1.1% | +26.1% | +26.4% |